Company Filing History:
3 out of 193 
1 out of 2,078 
1 out of 1,361 
Years Active: 2017-2021
Title: Betty Chang: Innovator in BTK Inhibitor Research
Introduction
Betty Chang is a prominent inventor based in Cupertino, CA, known for her significant contributions to the field of biotechnology. She holds a total of 3 patents that focus on advancements in Bruton's Tyrosine Kinase (BTK) inhibitors, which are crucial in treating various B-cell malignancies.
Latest Patents
One of her latest patents is titled "Mutations associated with resistance to inhibitors of Bruton's Tyrosine Kinase (BTK)." This patent describes mutations that confer resistance to treatment with a BTK inhibitor. It also details modified BTK polypeptides that exhibit decreased inhibition to a covalent and/or irreversible BTK inhibitor. Furthermore, it outlines modifications of PLCy2 and CARD 11 polypeptides that confer resistance to treatment with a BTK inhibitor. The patent includes diagnostic methods for detecting the modified polypeptides and nucleic acids encoding them, as well as applications of these methods. Another significant patent is "Bruton's tyrosine kinase inhibitor combinations and uses thereof." This patent discloses methods, compositions, and kits for treating B-cell malignancies by administering a combination of a BTK inhibitor, such as ibrutinib, and a PIM inhibitor. It also addresses methods for treating BTK-resistant B-cell malignancies.
Career Highlights
Betty Chang has worked with notable companies in the pharmaceutical industry, including Pharmacyclics, Inc. and Janssen Pharmaceutica NV. Her work has significantly impacted the development of therapies for B-cell malignancies, showcasing her expertise in the field.
Collaborations
Throughout her career, Betty has collaborated with esteemed colleagues, including Joseph J Buggy and Hsu-Ping Kuo. These collaborations have further enhanced her research and contributions to biotechnology.
Conclusion
Betty Chang's innovative work in the field of BTK inhibitors has made her a key figure in biotechnology. Her patents and collaborations reflect her dedication to advancing treatments for B-cell malignancies.